RVNC Revance Therapeutics, Inc. Stock Quote

RVNC [NASD]

Index	-	P/E	-	EPS (ttm)	-4.72	Insider Own	1.80%	Shs Outstand	67.46M	Perf Week	-4.88%
Market Cap	1.95B	Forward P/E	-	EPS next Y	-3.67	Insider Trans	-8.23%	Shs Float	65.68M	Perf Month	2.04%
Income	-303.40M	PEG	-	EPS next Q	-1.15	Inst Own	88.90%	Short Float	5.52%	Perf Quarter	-13.77%
Sales	47.10M	P/S	41.48	EPS this Y	-32.60%	Inst Trans	6.07%	Short Ratio	9.06	Perf Half Y	-4.71%
Book/sh	2.76	P/B	9.60	EPS next Y	23.70%	ROA	-44.10%	Target Price	38.80	Perf Year	-22.77%
Cash/sh	4.56	P/C	5.81	EPS next 5Y	11.60%	ROE	-103.10%	52W Range	22.89 - 34.62	Perf YTD	-6.53%
Dividend	-	P/FCF	-	EPS past 5Y	-10.00%	ROI	-48.80%	52W High	-23.48%	Beta	1.25
Dividend %	-	Quick Ratio	6.00	Sales past 5Y	119.60%	Gross Margin	69.40%	52W Low	15.73%	ATR	1.02
Employees	470	Current Ratio	6.10	Sales Q/Q	22829.30%	Oper. Margin	-	RSI (14)	42.68	Volatility	4.43% 3.55%
Optionable	Yes	Debt/Eq	1.50	EPS Q/Q	4.20%	Profit Margin	-	Rel Volume	0.83	Prev Close	26.52
Shortable	Yes	LT Debt/Eq	1.50	Earnings	Aug 05 AMC	Payout	-	Avg Volume	399.90K	Price	26.49
Recom	1.80	SMA20	-1.79%	SMA50	-6.87%	SMA200	-5.73%	Volume	332,217	Change	-0.11%

Oct-15-20

Reiterated

Needham

Buy

$36 → $42

Aug-11-20

Resumed

Mizuho

Buy

$32

Mar-23-20

Downgrade

Goldman

Buy → Neutral

$32 → $15

Dec-02-19

Initiated

Goldman

Buy

Oct-30-19

Upgrade

Wells Fargo

Market Perform → Outperform

$20

Jun-11-19

Initiated

Barclays

Overweight

$28

Feb-15-19

Initiated

Wells Fargo

Market Perform

Feb-14-19

Initiated

H.C. Wainwright

Buy

$25

Jan-29-19

Initiated

Stifel

Buy

$50

Nov-16-18

Upgrade

Guggenheim

Neutral → Buy

Sep-17-18

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Apr-20-18

Reiterated

Mizuho

Buy

$54 → $48

Mar-27-18

Initiated

Needham

Buy

$42

Mar-05-18

Initiated

Goldman

Buy

$60

Jan-09-18

Downgrade

Guggenheim

Buy → Neutral

Dec-06-17

Reiterated

Mizuho

Buy

$37 → $54

Dec-06-17

Initiated

Guggenheim

Buy

$42

Nov-27-17

Initiated

Barclays

Overweight

$31

Nov-17-17

Initiated

Mizuho

Buy

$37

Aug-22-17

Initiated

JMP Securities

Mkt Outperform

$34

Sep-16-21 08:00AM	Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021 Business Wire
Sep-13-21 11:46AM	Those who invested in Revance Therapeutics (NASDAQ:RVNC) five years ago are up 62% Simply Wall St.
Sep-10-21 08:00AM	Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting Business Wire
Sep-02-21 08:00AM	Revance to Participate in the Wells Fargo Securities Healthcare Conference Business Wire
Sep-01-21 08:00AM	Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery Business Wire
Aug-05-21 07:05PM	Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update Business Wire
Jul-29-21 03:05PM	Analysts Estimate Revance Therapeutics, Inc. (RVNC) to Report a Decline in Earnings: What to Look Out for Zacks
08:00AM	Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 Business Wire
Jul-12-21 09:35AM	How Much Of Revance Therapeutics, Inc. (NASDAQ:RVNC) Do Institutions Own? Simply Wall St.
Jun-03-21 05:39AM	Does Revance Therapeutics Have Any Wrinkles? TheStreet.com
May-26-21 04:05PM	Revance to Participate in Upcoming Virtual Healthcare Conferences Business Wire +5.80%
08:00AM	Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection Business Wire
May-11-21 08:17AM	Is Revance Therapeutics (NASDAQ:RVNC) Weighed On By Its Debt Load? Simply Wall St.
May-10-21 06:05PM	Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update Business Wire
02:30PM	Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-21 08:00AM	Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021 Business Wire
Apr-29-21 12:34PM	Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q1 Earnings Expected to Decline Zacks
Apr-27-21 04:05PM	Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinAs 24-Week Long Duration Profile Across Multiple Female Age Cohorts Business Wire
08:00AM	Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma Business Wire
Apr-23-21 08:00AM	Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021 Business Wire
Apr-06-21 04:05PM	Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference Business Wire
Apr-01-21 08:00AM	Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting Business Wire
Mar-22-21 04:05PM	Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021 Business Wire
11:05AM	Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength? Zacks
Mar-12-21 04:06AM	Investors Who Bought Revance Therapeutics (NASDAQ:RVNC) Shares A Year Ago Are Now Up 73% Simply Wall St.
Feb-24-21 04:05PM	Revance to Participate in Upcoming Virtual Healthcare Conferences Business Wire
Feb-23-21 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga
05:58AM	Revance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb Spasticity Benzinga
Feb-22-21 05:25PM	Recap: Revance Therapeutics Q4 Earnings Benzinga
04:05PM	Revance Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
04:05PM	Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity Business Wire
02:30PM	Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM	Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey OConnor Kolaja, to its Board of Directors Business Wire
Feb-19-21 10:40AM	Revance Therapeutics's Earnings Outlook Benzinga
Feb-12-21 08:00AM	Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021 Business Wire
Jan-25-21 08:00AM	Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021 Business Wire
Jan-22-21 08:00AM	Revance Issues Inaugural Environmental, Social and Governance (ESG) Report Business Wire
Jan-19-21 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-11-21 07:45AM	What Is The Ownership Structure Like For Revance Therapeutics, Inc. (NASDAQ:RVNC)? Simply Wall St.
Jan-07-21 04:05PM	Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference Business Wire +8.79%
08:00AM	Revance Provides Corporate Update and Anticipated Milestones for 2021 Business Wire
Dec-23-20 01:30PM	Stocks Showing Improved Relative Strength: Revance Therapeutics Investor's Business Daily
Dec-22-20 08:00AM	Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection PR Newswire
Dec-21-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-17-20 08:05AM	Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study Business Wire +5.83%
Dec-16-20 08:30AM	Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville Business Wire
Dec-14-20 10:47AM	Is RVNC A Good Stock To Buy Now? Insider Monkey
Nov-27-20 01:31PM	Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed Zacks
Nov-25-20 08:30AM	FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection Business Wire
Nov-24-20 04:05PM	Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-20-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-11-20 08:08AM	Analysts Have Made A Financial Statement On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Third-Quarter Report Simply Wall St.
Nov-10-20 04:05PM	Revance to Participate in the Stifel 2020 Virtual Healthcare Conference Business Wire -6.76%
08:40AM	The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga
Nov-09-20 05:16PM	Recap: Revance Therapeutics Q3 Earnings Benzinga
04:05PM	Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire
04:05PM	Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis Business Wire
02:45PM	Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-20 09:00AM	Is a Surprise Coming for Revance (RVNC) This Earnings Season? Zacks
Nov-03-20 04:05PM	Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference Business Wire
Nov-02-20 04:05PM	Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020 Business Wire
Oct-23-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.82%
Oct-14-20 08:00AM	Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia Business Wire -7.68%
Oct-06-20 08:00AM	Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting Business Wire
Oct-05-20 10:15AM	3 Strong Buy Healthcare Stocks With Major Catalysts Approaching TipRanks
Sep-23-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-08-20 04:05PM	Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Sep-02-20 08:00AM	Revance to Participate in the Wells Fargo Securities Healthcare Conference Business Wire
Aug-28-20 11:29AM	Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet? Simply Wall St.
Aug-25-20 08:00AM	Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers Business Wire
Aug-11-20 08:30AM	Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery Business Wire
Aug-06-20 04:05PM	Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update Business Wire
Jul-30-20 04:05PM	Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Business Wire
Jul-24-20 09:46AM	Revance Completes All-Stock Deal For HintMDs Payments Platform TipRanks
Jul-23-20 06:20PM	Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices Business Wire
Jul-05-20 03:28PM	Is Revance Therapeutics Inc (RVNC) Going to Burn These Hedge Funds? Insider Monkey
Jun-30-20 04:05PM	Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection Business Wire
08:00AM	Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crows Feet, Respectively Business Wire
Jun-26-20 09:57AM	Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher Zacks
Jun-18-20 12:27PM	Needham: 3 Conviction Buy Stocks to Snap up Now TipRanks
Jun-09-20 08:10PM	Edited Transcript of RVNC earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-04-20 04:05PM	Revance to Participate in the 40th Annual William Blair Growth Stock Conference Business Wire
Jun-02-20 04:05PM	Revance to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast Business Wire
03:31AM	Revance, Mylan Move Forward With Botox Rival; Analyst Sees Long Path Ahead SmarterAnalyst
Jun-01-20 08:30AM	Revance and Mylan to Advance Development Program for Biosimilar to BOTOX® Business Wire
May-20-20 08:12AM	Revance Acquires HintMD In All-Stock Deal, Analyst Praises Bold Step Forward SmarterAnalyst
May-19-20 08:01AM	Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices Business Wire
May-09-20 10:01PM	Revance Therapeutics (RVNC) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:05PM	Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update Business Wire
May-01-20 08:30AM	Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020 Business Wire -6.48%
Apr-30-20 04:05PM	Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 Business Wire
Apr-27-20 09:16AM	Revance's Shares March Higher, Can It Continue? Zacks +9.24%
Apr-21-20 08:05AM	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors GlobeNewswire
Apr-09-20 08:55AM	How Revance (RVNC) Stock Stands Out in a Strong Industry Zacks +8.05%
Apr-07-20 04:05PM	Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference Business Wire
Mar-26-20 04:05PM	Revance Provides Corporate Update in Light of COVID-19 Business Wire
Mar-25-20 08:36AM	Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options Zacks +5.36%

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rankin Aubrey	President, Innovation & Tech	Aug 16	Sale	26.34	9,364	246,659	65,463	Aug 17 06:20 PM
Rankin Aubrey	President, Innovation & Tech	Jul 28	Sale	30.06	54,332	1,632,960	154,302	Jul 30 08:57 PM
Rankin Aubrey	President, Innovation & Tech	Jul 26	Sale	29.72	55,382	1,645,953	355,943	Jul 28 09:48 PM
Rankin Aubrey	President, Innovation & Tech	Apr 05	Sale	28.28	2	57	411,325	Apr 06 07:41 PM
Rankin Aubrey	President, Innovation & Tech	Mar 04	Sale	25.43	33,119	842,216	411,327	Mar 05 08:10 PM
Rankin Aubrey	President, Innovation & Tech	Feb 01	Sale	25.95	33,119	859,438	444,446	Feb 03 08:13 PM
Rankin Aubrey	President, Innovation & Tech	Dec 30	Sale	27.82	33,119	921,212	477,565	Jan 04 08:01 PM
Rankin Aubrey	President, Innovation & Tech	Nov 30	Sale	23.85	33,119	789,888	510,684	Dec 02 08:55 PM
Rankin Aubrey	President, Innovation & Tech	Oct 29	Sale	26.15	33,119	865,949	543,803	Oct 30 08:24 PM
Rankin Aubrey	President, Innovation & Tech	Sep 28	Sale	26.18	33,119	867,055	576,922	Sep 30 09:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience